ViewRay to host Investor Day
ViewRay announced plans for an Investor Day on November 17, 2022, at 8:00 a.m. Eastern Time in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ViewRay announced plans for an Investor Day on November 17, 2022, at 8:00 a.m. Eastern Time in New York City. The event will include presentations from the leadership team detailing business progress and future initiatives. A webcast will be available for those who cannot attend in person, and registration can be completed via the ViewRay website.
ViewRay, listed on NASDAQ as VRAY, specializes in the design and manufacturing of the MRIdian MR-Guided Radiation Therapy System, addressing unique challenges in radiation oncology.
Details
News Market Reaction – VRAY
The recorded move for VRAY in the trading session of this news was +3.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, Oct. 3, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today plans to host an Investor Day on Thursday, November 17, 2022, at 8:00 a.m. Eastern Time in New York City, NY.
The event will feature presentations from the ViewRay leadership team on business progress and future plans.
A simultaneous webcast and replay of the Company's presentation will be available on ViewRay's website. To register for the webcast please visit ViewRay's website.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
View original content:https://www.prnewswire.com/news-releases/viewray-to-host-investor-day-301638404.html
SOURCE ViewRay, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.